| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Thin layer chromatography was used to measure how dose-dependently galangin (Norizalpinin) blocks the downstream activation of DMBA. Moreover, galangin prevents DMBA-DNA adducts and DMBA-induced cell proliferation. As shown by O-determinase activity in intact cells and by isolated microsomes from DMBA-treated cells, galangal produced a strong dose-dependent suppression of CYP1A1 activity. The results of the double reciprocal plot analysis of inhibition kinetics indicate that galangal, as opposed to non-galangin, increased the levels of CYP1A1 mRNA, indicating that it may be an agonist of the aryl hydrocarbon receptor. However, it inhibits the induction of CYP1A1 mRNA by -p-dioxin (TCDD) or DMBA. Moreover, galangin prevents the control of reporter vectors carrying the CYP1A1 promoter by TCDD or DMBA [1]. Cells are treated with galangin to induce autophagy (at 130 μM) and labeling (at 370 μM). Specifically, treatment of HepG2 cells with galangin results in a rise in microtubule-associated protein light chain 3 levels, an accumulation of autophagosomes, and an increase in the percentage of cells within the vacuole. Additionally, p53 expression is elevated. While overexpressing p53 in Hep3B cells returns the majority of galangin-induced vacuolated cells to normal levels, p53 inhibition in HepG2 cells alleviates galangin-induced autophagy [2].
|
|---|---|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Galangin has known human metabolites that include (2S,3S,4S,5R)-6-(5,7-dihydroxy-4-oxo-2-phenylchromen-3-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid, Kaempferol, and (2S,3S,4S,5R)-6-(3,5-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid. |
| References | |
| Additional Infomation |
Galangin is a 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells. It has a role as an antimicrobial agent, an EC 3.1.1.3 (triacylglycerol lipase) inhibitor and a plant metabolite. It is a trihydroxyflavone and a 7-hydroxyflavonol.
Galangin has been reported in Camellia sinensis, Apis, and other organisms with data available. |
| Molecular Formula |
C15H10O5
|
|---|---|
| Molecular Weight |
270.24
|
| Exact Mass |
270.052
|
| CAS # |
548-83-4
|
| Related CAS # |
Galangin-13C3
|
| PubChem CID |
5281616
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
518.6±50.0 °C at 760 mmHg
|
| Melting Point |
214-215 °C(lit.)
|
| Flash Point |
202.0±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
2.83
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
424
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VCCRNZQBSJXYJD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H
|
| Chemical Name |
3,5,7-trihydroxy-2-phenylchromen-4-one
|
| Synonyms |
Norizalpinin Galangin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~462.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7004 mL | 18.5021 mL | 37.0041 mL | |
| 5 mM | 0.7401 mL | 3.7004 mL | 7.4008 mL | |
| 10 mM | 0.3700 mL | 1.8502 mL | 3.7004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
